Neudle.com: "cabergoline"

Differential
(Click to cross reference)

acromegaly

advances in neurology

adverse drug reaction

amenorrhea

aortic valve, lesion of

bromocriptine

cabergoline

chest x-ray, abnormal

complications

congestive heart failure

cough

cranial nerve palsies

echocardiogram, transthoracic

iatrogenic neurologic disorders

medication withdrawal

microsurgery

microsurgery, transsphenoidal

mitral valve lesion

mitral valve regurgitation

mortality

MRI

MRI, abnormal

MRI, contrast enhanced

neoplasm, pituitary

neoplasm, pituitary, treatment of

neuroendocrinology

neurologic disease, diagnoses of

neurologic symptoms

octreotide

Parkinson disease

Parkinson disease, fluctuations in

Parkinson disease, on-off phenomena in

Parkinson disease, treatment of

pituitary, enlargement

pituitary, hormones of

pituitary, lesion of

pituitary, microadenoma

pleural effusion

pleural fibrosis

polyps, gastrointestinal tract

radiation therapy, CNS treatment and complications with

radiation therapy, stereotactic

restless leg syndrome

review article

risk factors

risk-benefit assessment

ropinirole

rotigotine

safety

sella turcica, enlargement of

sinemet

somatostatin analogue

testicular atrophy

treatment of neurologic disorder

tricuspid valve, lesion of

Showing articles 0 to 20 of 20

Practice Guideline Summary: Treatment of Restless Leg Syndrome in Adults
Neurol 87:2585-2593, Winkelman, J.W.,et al, 2016

Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010

Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007

Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007

Efficacy of Cabergoline in Restless Legs Syndrome, A Placebo-Controlled Study with Polysomnography (CATOR)
Neurol 67:1040-1046, Oertel,W.H.,et al, 2006

Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006

Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006

Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005

Effective Cabergoline Treatment in Idiopathic Restless Legs Syndrome
Neurol 63:2272-2279, Stiasny-Kolster,K.,et al, 2004

Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003

Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003

Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000

Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998

Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa
Neurol 48:363-368, Rinne,U.K.,et al, 1997

Multicenter, Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson's Disease
Neurol 46:1062-1065, Hutton,J.T.,et al, 1996

Double-Blind Comparison of Cabergoline & Bromocriptine in Parkinson's Disease Pts with Motor Fluctuations
Neurol 47:785-788, Inzelberg,R.,et al, 1996

Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline
Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994

Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993

Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993

Pleuropulmonary Disease Associated with Dopamine Agonist Therapy
Ann Neurol 30:613-616, Bhatt,M.H.,et al, 1991

Showing articles 0 to 20 of 20